Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?

• Published in: Nature clinical practice. Oncology Vol. 3; no. 12; pp. 668 - 681
• Main Authors: Muranski, Pawel, Restifo, Nicholas P, Boni, Andrea, Wrzesinski, Claudia, Citrin, Deborah E, Rosenberg, Steven A, Childs, Richard
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.12.2006
• Subjects: Adoptive immunotherapy; Adoptive transfer; Animals; Care and treatment; Clinical Trials as Topic; Cyclophosphamide; Disease Models, Animal; Fludarabine; Health aspects; Hematopoietic stem cells; Humans; Immune system; Immunoregulation; Immunosuppression; Immunotherapy; Immunotherapy, Adoptive; Lymphocytes T; Lymphocytes, Tumor-Infiltrating; Melanoma; Metastases; Neoplasms - immunology; Neoplasms - therapy; Prevention; Risk factors; Solid tumors; T cell receptors; T-Lymphocytes, Regulatory - immunology; United States
• ISSN: 1743-4254; 1759-4774; 1743-4262; 1759-4782
• DOI: 10.1038/ncponc0666

In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive conditioning with fludarabine and cyclophosphamide resulted in a 50% response rate in robust long-term persistence of adoptively transferred T cells. Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system ('cytokine sinks'). Newly emerging animal data suggest that more profound lymphoablative conditioning with autologous hematopoetic stem-cell rescue might further enhance treatment results. Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning. We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice.